These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 35283317)
1. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Mustafayev K; Torres H Clin Microbiol Infect; 2022 Oct; 28(10):1321-1327. PubMed ID: 35283317 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Chiu CY; Ahmed S; Thomas SK; Wang LS; Mustafayev K; Fayad LE; Wierda WG; Khawaja F; Torres HA Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):610-615. PubMed ID: 37150651 [TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204. Hwang JP; Arnold KB; Unger JM; Chugh R; Tincopa MA; Loomba R; Hershman D; Ramsey SD Support Care Cancer; 2022 Dec; 31(1):93. PubMed ID: 36585488 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470 [TBL] [Abstract][Full Text] [Related]
5. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Mustafayev K; Mallet V; Torres HA J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408 [TBL] [Abstract][Full Text] [Related]
6. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Piaserico S; Messina F; Russo FP Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626 [TBL] [Abstract][Full Text] [Related]
7. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741 [TBL] [Abstract][Full Text] [Related]
9. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV). Blackard JT; Sherman KE Rev Med Virol; 2018 Jul; 28(4):e1984. PubMed ID: 29761585 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review. Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444 [TBL] [Abstract][Full Text] [Related]
14. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. Bonifati C; Lora V; Graceffa D; Nosotti L World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880 [TBL] [Abstract][Full Text] [Related]
15. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy. Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368 [TBL] [Abstract][Full Text] [Related]
16. [Mechanism and clinical significance of HBV reactivation after anti-HCV therapy]. Zeng WJ; Gao L; Xu YW; Chen XM; Wang FS; Lu FM Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):997-1001. PubMed ID: 36299197 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Pisaturo M; Macera M; Alessio L; Calò F; Coppola N Viruses; 2019 Sep; 11(9):. PubMed ID: 31540223 [TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. Aggeletopoulou I; Konstantakis C; Manolakopoulos S; Triantos C World J Gastroenterol; 2017 Jun; 23(24):4317-4323. PubMed ID: 28706414 [TBL] [Abstract][Full Text] [Related]
19. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. Huang SC; Cheng PN; Liu CH; Yang HC; Su TH; Tseng TC; Chen PJ; Kao JH; Liu CJ J Formos Med Assoc; 2022 May; 121(5):920-929. PubMed ID: 34538552 [TBL] [Abstract][Full Text] [Related]
20. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]